On 16 June, the primary investigators of the UK’s RECOVERY trial announced that the commonly used, low-price corticosteroid dexamethasone has proven to be a potentially life-saving new treatment option for those critically ill with Covid-19 and requiring respiratory support.
It’s low cost, wide availability and easy administration is what makes dexamethasone’s success in Covid-19 patients on oxygen or ventilators so special.
The UK Government’s chief scientific adviser Sir Patrick Vallance stated: “It is particularly exciting as this is an inexpensive, widely available medicine. This is a ground-breaking development in our fight against the disease.”
Read the full article here.